Global Bio/Pharma CapEx Soars, Would Rather ‘Make Than Buy,’ Says PharmSource
September 23, 2016
2015 Proves to be a Disappointing Year for Dose CMO Industry Growth
September 9, 2016
ADC Opportunity: Big Risk Vs. Big Payoff for CMO Industry
February 8, 2016
Dose CMO Industry Growth Not Sustainable, Despite Outpacing Overall Bio/Pharma Industry
September 1, 2015
Pharma CMOs left behind as biosimilars heat up
January 29, 2015
Pharma in-licensing of NMEs signals new business for contract manufacturers
January 12, 2015
PharmSource report details factors driving bio/pharm development spending
December 2, 2014
Big bio/pharma would rather ‘make than buy,’ says PharmSource
November 11, 2014
PharmSource re-engineers content-rich website, launches new blog
October 28, 2014
European drug pricing to affect CMO profitability, future performance
July 14, 2014
Pharma industry’s capacity to produce cytotoxic injectable drugs constricts
June 25, 2014
PharmSource Lead Sheet: New Platform Adds Functionality, Dynamic Interface
May 8, 2014
PharmSource Report: CMOs Fail to Gain Share of NDA Approvals
April 8, 2014
New In-Depth Report on Demand and Supply for Contract Manufacturing of Conventional Injectable Drugs Through 2019
December 6, 2013
Bio/Pharmaceutical Contract Manufacturing – Industry Analysis of Dose Manufacturing by the Numbers: Composition, Size, Market Shares, Profitability and Outlook
September 4, 2013
Analysis of 2012 New Drug Application Approvals (NDAs) Shows Bio/Pharma Contract Manufacturers Treading Water
April 12, 2013
Periscope Sign up for our business development newsletter
For those who serve bio/pharma, medical device and diagnostic companies.
PharmSource STRATEGIC ADVANTAGE
Outsourcing intelligence portal with hard-to-find intelligence on CMO/CDMO manufacturing capabilities; approved products manufactured by CMOs; emerging markets; expert trend reports, and more. Learn more.
PharmSource Lead Sheet
Targeted new business opportunities for companies selling goods or services to bio/pharmaceutical companies and medical device/diagnostic companies around the world. Learn more.
CMOs and CROs Have Different Trajectories
A growing number of observers, including the Wall Street analysts that follow the publicly-traded CROs and CMOs, have made statements recently suggesting that the CMO industry is following the trajectory that… See Jim Miller’s Outsourcing Outlook Archive.
Testimonial
“In less than four months of using the PharmSource service, we converted a lead to an awarded early phase study for over $3M. That’s an impressive ROI that competing services are unable to replicate.”
Read more from other satisfied clients.